Eluting Patch Technology

multilayer, intra-oral
drug delivery platform

GCANRx has the exclusive worldwide license for PharMedica’s Eluting Transmucosal Patch Platform (ETP) for non-invasive drug delivery in the Cannabis field.

The company holds the rights to new delivery technologies using a bio-adhesive, adjustable dose, and fully dissolvable, non-irritant patch, which provides for a needle free, intra-oral systemic drug delivery. The conveyance technology is designed to accelerate and enhance the delivery and bioavailability of medicines and cannabis actives when compared to traditional methods of enteral administration.

Lower Dosing

The transmembrane functionality enables needle-free, transmucosal drug delivery, administering the medicine directly into the blood system while bypassing the digestive and hepatic systems, thereby increasing the bioavailability and lowering the dose required to achieve desired therapeutic effects.


The mucoadhesive film is applied on the internal mouth, and is made of multiple dosage form layers, enabling loading of different dosages on the same thin film patch.

“By improving the bioavailability of cannabinoids molecules we can deliver lower doses of actives while achieving greater therapeutic efficacy.”

- Aitan Zacharin, CEO of GCANRx

Controlled Release

Two or more layers of the Eluting Patch offers diverse timing of drug administration. The inner film layer is attached to the membrane providing fast release, followed by the outer film layers providing a slow and sustained release.


Each layer contains similar or different drugs, depending of the purpose of the medical treatment.


  • Rapid onset with slow and sustained release
  • Bio-adhesion- firmly attached yet totally non-irritant
  • Rapid onset with slow and sustained release
  • Flexible, manageable, and unnoticeably thin
  • Needle-free systemic
  • Fully dissolvable- disintegrates and dissolves as the treatment progresses